Last reviewed · How we verify
antidiabetics
antidiabetics is a Small molecule drug developed by IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. It is currently in Phase 3 development.
Antidiabetics are medications used to treat diabetes mellitus by decreasing glucose levels in the blood. They can be administered orally or by injection, with some examples including SGLT-2 inhibitors and GLP-1 receptor agonists, which are small molecule drugs.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | antidiabetics |
|---|---|
| Sponsor | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- Restoration of Hypoglycemia Awareness With Metoclopramide (PHASE2)
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- The Use of Advanced Imaging in HFpEF
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (PHASE3)
- A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antidiabetics CI brief — competitive landscape report
- antidiabetics updates RSS · CI watch RSS
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy portfolio CI
Frequently asked questions about antidiabetics
What is antidiabetics?
Who makes antidiabetics?
What development phase is antidiabetics in?
Related
- Manufacturer: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing